Early data from a trial evaluating Cue Biopharma Inc's (NASDAQ: CUE) CUE-101 combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) demonstrated that two out of four patients in dose-escalation cohorts had partial responses.
The other two patients are showing reductions in target lesions.
CUE-101, which targets IL-2, is under development as a potential third-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma.
CUE-101 + pembrolizumab combination therapy is under examination as a front-line treatment.
Updated data on the dose-expansion CUE-101 as a monotherapy trial showed a 50% clinical benefit rate.
The Company plans to file an Investigational New Drug (IND) application for CUE-102, another candidate from IL-2 based CUE-100 series, in Q1 of 2022.
In January, the Company received a $3 million milestone payment from LG Chem Life Sciences under an agreement for CUE-102.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.